8-K: BioMarin Completes Acquisition of Inozyme Pharma, Shares Delisted from Nasdaq

BioMarin Pharmaceutical Inc. has successfully completed its acquisition of Inozyme Pharma, Inc. for $4.00 per share in cash, resulting in Inozyme becoming a wholly-owned subsidiary and its shares being delisted from the Nasdaq Global Select Market.

Summary

• BioMarin Pharmaceutical Inc. completed its acquisition of Inozyme Pharma, Inc. on July 1, 2025, pursuant to a Merger Agreement dated May 16, 2025.
• The acquisition was executed through a tender offer by BioMarin's subsidiary, Incline Merger Sub, Inc., to acquire all outstanding shares of Inozyme common stock at an Offer Price of $4.00 per share in cash.
• The tender offer, which commenced on June 2, 2025, expired on June 30, 2025, with 45,455,118 shares validly tendered and not withdrawn, representing approximately 69.8% of Inozyme's total outstanding shares.
• Following the tender offer, Incline Merger Sub, Inc. merged with and into Inozyme on July 1, 2025, with Inozyme continuing as the surviving corporation and a wholly-owned subsidiary of BioMarin.
• At the effective time of the merger, each Inozyme share (not already tendered or held by BioMarin/Purchaser, or subject to appraisal rights) was converted into the right to receive the $4.00 per share Merger Consideration.
• In connection with the acquisition, Inozyme's 2020 Employee Stock Purchase Plan was terminated effective June 30, 2025.
• All in-the-money Company Options and Company RSUs automatically accelerated, became fully vested, and were converted into cash payments based on the Offer Price, while out-of-money options were cancelled without consideration.
• Inozyme's common stock was delisted from the Nasdaq Global Select Market effective before the opening of trading on July 1, 2025, and Inozyme intends to terminate its SEC registration and reporting obligations.

Sentiment

Score: 7

Explanation: The sentiment is positive for Inozyme shareholders who received a cash payout for their shares, representing a successful exit for the company as an independent entity. The completion of the acquisition provides certainty.

Positives

• Inozyme shareholders who tendered their shares received a cash payment of $4.00 per share, providing liquidity and a defined return on their investment.
• The completion of the acquisition provides certainty for Inozyme's operations and programs under the ownership of BioMarin.

Negatives

• Inozyme Pharma, Inc. ceases to exist as an independent publicly traded entity, with its common stock delisted from Nasdaq.
• All outstanding Company Options with an exercise price equal to or greater than the Offer Price were cancelled without any consideration.

Risks

• The primary risk for shareholders was the tender offer not completing, which was mitigated by the successful acquisition.
• Shareholders who did not tender their shares and did not properly exercise appraisal rights received the Merger Consideration without interest, potentially missing out on higher value if the stock had traded above the offer price prior to the merger.

Future Outlook

Inozyme Pharma, Inc. will operate as a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., and its public reporting obligations under the Exchange Act will be terminated.

Industry Context

This acquisition represents a consolidation within the biotechnology and pharmaceutical sectors, where larger companies often acquire smaller, specialized firms to expand their pipeline or gain access to specific technologies or patient populations. The integration of Inozyme into BioMarin suggests a strategic alignment to leverage Inozyme's assets within BioMarin's broader portfolio.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received $4.00 per share in cash for their tendered shares, providing a definitive return and liquidity. Those who did not tender or exercise appraisal rights will also receive this consideration.
• Employees: The 2020 Employee Stock Purchase Plan was terminated, and equity awards (in-the-money options and RSUs) were converted to cash, impacting employee compensation and benefits.
• Management: The previous board of directors and executive officers resigned, and new directors and officers were appointed, reflecting the change in control.

Next Steps

• Inozyme intends to file a Form 15 with the SEC to terminate the registration of its shares under Section 12(g) of the Exchange Act and suspend its reporting obligations under Sections 13 and 15(d) of the Exchange Act.

Key Dates

Keywords

Inozyme Pharma, BioMarin Pharmaceutical, Acquisition, Merger, Tender Offer, Delisting, SEC Filing, 8-K, Biotechnology, Pharmaceuticals, Corporate Action, Shareholder Value